Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

Kodiak's geochemical work in 2024 corroborated copper in known target areas. Highly anomalous copper values up to 960 ppm were returned from the soil sampling. Kodiak is planning broader soil ...

Kodiak collected a total of 38 rock samples from prospecting on the MPD Northwest claim block in 2024. The focus was to obtain representative samples from most mineralized targets to confirm grades ...

The following is a summary of “ALS Motor Observational Telemedicine Objective Rasch-Built Assessment,” published in the ...

Somaya Critchlow, 31, is showing her provocative paintings alongside a storied collection that includes work by Rubens, van ...

The Pulitzer-prize winning writer and essayist talks about his love of art and how he reconciles two challenging roles.

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...